Valuing InnovationBalancing Act: Comparative Effectiveness Research and Innovation in U.S. Healthcare
NEHI | April 20, 2009
The National Network for Health Innovation provides a framework for designing and implementing a federal CER program that will sustain innovation in healthcare.
Comparative Effectiveness Research: Effect on Pharmaceutical Innovation, Value of Health, and Longevity
CMPI | May 2011
John Vernon, PhD, and Bob Goldberg, PhD, explore the potential impact of CER on innovation, health, and even the length of people's lives.
Comparative Effectiveness Research (CER) and Innovation: Policy Options to Foster Medical Advances
National Institute for Health Care Reform | October 5, 2010
By promoting effective therapies, CER could increase rewards and incentives for beneficial innovations in medicine. However, it could also dampen the development of new, potentially effective therapies by creating additional hurdles for innovators. This paper explores the steps that could help ensure that CER encourages beneficial innovation.
Framing the Debate-Untangling the Potential Impact of Comparative Effectiveness Research on Innovation
Avalere Health | November 2009
This paper explores potential impacts of CER on pharmaceutical investments and innovation.
The Kennedy Study
Commissioned by Professor Sir Ian Kennedy, this study aims to respond to the concerns surrounding innovation.
Medical Innovation: Promises and Pitfalls
The Brookings Institution | Winter 2003
Alan M. Garber and Victor Fuchs discuss explain the dynamic relationship between spending and innovation.
Progress at Work: The Value of Innovation PIPC A resource from the Partnership to Improve Patient Care (PIPC) that explores innovation and CER.
Promoting Biomedical Innovation and Economic Value: New Models for Reimbursement and Evidence Development
Brookings | April 22, 2010
The Engelberg Center for Health Care Reform and the Leonard D. Schaeffer Center for Health Policy and Economics at USC hosted an event where key stakeholders discussed how to promote a system that fosters biomedical innovation and promotes economic value in the delivery of health care. Speakers included Dana Goldman, Mark McClellan, Newt Gingrich, Peter Orszag, and more.
Should U.S. Import U.K. Model for Medicare and Medicaid?
Forbes.com | October 5, 2010
Tomas J. Philipson discusses why controlling costs is important, but shouldn’t come at the expense of future innovations.
The Silver Book: Chronic Disease and Medical Innovation in an Aging Nation
Alliance for Aging Research
This almanac of statistics on the burden of chronic disease and the value of medical research in reducing burden, shares highlights from studies and reports that help make the case for innovation.
Use of Comparative Effectiveness Research in Drug Coverage and Pricing Decisions: A six-country comparison.
The Commonwealth Fund | July 2, 2010
Corinna Sorenson provides information on the role and use of cost effectiveness research in coverage and pricing decisions in Denmark, England, France, Germany, the Netherlands, and Sweden.